About: Panobinostat   Goto Sponge  NotDistinct  Permalink

An Entity of Type : yago:Medicine103740161, within Data Space : wasabi.inria.fr associated with source document(s)

Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). Panobinostat was approved for medical use in the United States in February 2015, and in the European Union in August 2015. However, in March 2022, it was withdrawn in the United States.

AttributesValues
type
label
  • Panobinostat
  • Panobinostat
  • Panobinostat
  • パノビノスタット
comment
  • パノビノスタット（Panobinostat）は多発性骨髄腫の治療に用いられるヒドロキサム酸誘導体である。非選択的(DAC阻害薬)の一つである。商品名ファリーダック、ノバルティスファーマが製造販売。開発コードLBH-589。
  • Panobinostat (LBH-589) é um fármaco em testes que poderá ser utilizado em casos de câncer. Trata-se de um inibidor potente de HDAC (histone deacetylase). É desenvolvido pela Novartis e desde 2008 está sendo testado em casos de linfoma cutâneo de células T, leucemia mieloide crônica, câncer de mama e próstata e outros tipos severos de câncer.
  • El panobinostat (LBH-589) es un fármaco experimental desarrollado por Novartis para el tratamiento del cáncer. Desde diciembre de 2008, se está probando su eficacia contra el (LCCT), leucemia mieloide crónica, síndrome mielodisplásico, cáncer de seno, cáncer de próstata y otros tipos de enfermedades en varios ensayos clínicos de fase II y III,​​ por ejemplo un estudio fase III para LCCT.​ Actualmente ya comercializado en EE. UU., y recientemente, Novartis® ha recibido la aprobación de la U.E. para Farydak®, el primer anticancerígeno de su clase aprobado para pacientes con múltiples mielomas.​
  • Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). Panobinostat was approved for medical use in the United States in February 2015, and in the European Union in August 2015. However, in March 2022, it was withdrawn in the United States.
sameAs
topic
depiction
  • External Image
described by
dbp:bioavailability
  • 21.0
dbp:drugbank
  • DB06603
dbp:eliminationHalfLife
  • 133200.0
dbp:excretion
  • Fecal , renal
dbp:kegg
  • D10319
dbp:legalStatus
  • Rx-only
dbp:tradename
  • Farydak
Subject
dbo:wikiPageID
dbo:wikiPageRevisionID
dbo:wikiPageWikiLink
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software